Among the common subtypes of breast cancer, BM preferentially develop in metastatic patients with HER2 -positive disease and triple-negative breast cancers (TNBC), which lack estrogen receptor (ER), progesterone receptor (PR), and HER2 alterations [3, 4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.